Lithium is still the mainstay in the treatment of affective disorders as a mood stabilizer. Lithium also shows some anticonvulsant properties. While the underlying mechanisms of action of lithium are not yet exactly understood, we used a model of clonic seizure induced by pentylenetetrazole (PTZ) in male NMRI mice to investigate whether the anticonvulsant effect of lithium is mediated via NO-cGMP pathway. Injection of a single effective dose of lithium chloride (25mg/kg) intraperitoneally (i.p.) increased significantly the seizure threshold (P<0.01). The anticonvulsant properties of the effective dose of lithium were prevented by pre-treatment with the per se non-effective doses of l-ARG [the substrate for nitric oxide synthase; NOS] (30 and 50mg/kg) or sildenafil [a phosphodiesterase 5 inhibitor] (10 and 20mg/kg). l-NAME [a non-specific NOS inhibitor] (5, 15 and 30mg/kg), 7-NI [a specific neural NOS inhibitor] (30 and 60mg/kg) or MB [a guanylyl cyclase inhibitor] (0.5 and 1mg/kg) augmented the anticonvulsant effect of a sub-effective dose of lithium (10mg/kg, i.p.). Whereas several doses of aminoguanidine [an inducible NOS inhibitor] (20, 50 and 100mg/kg) failed to alter the anticonvulsant effect of lithium. Our findings demonstrated that nitric oxide-cyclic GMP pathway could be involved in the anticonvulsant properties of the lithium chloride. In addition, the role of constitutive NOS versus inducible NOS is prominent in this phenomenon.